RECRUITING

Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Conditions

T-cell Lymphoma Cutaneous/Peripheral T-Cell Lymphoma Peripheral T-cell Lymphoma Peripheral T-Cell Lymphoma, Not Classified Primary Cutaneous T-cell Lymphoma Cutaneous T-Cell Lymphoma, Unspecified Cutaneous T-cell Lymphoma Follicular T-Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Sézary's Disease Mycosis Fungoides Lymphoma CTCL Sézary syndrome PTCL AITL cALCL

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Official Title

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion

Quick Facts

Study Start:2023-12-18

Study Completion:2025-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04234048

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* All patients must have histologically or cytologically confirmed diagnosis of the following specific types of T-cell lymphomas (TCL): 1. Cutaneous T-cell lymphoma (CTCL): mycosis fungoides (MF), Sézary Syndrome (SS), or primary cutaneous CD30+ anaplastic large cell lymphoma (cALCL). 2. Nodal TCL: Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), or follicular T-cell lymphoma (FTCL) as defined in the 2016 revision of the WHO classification of lymphoid malignancies\[98\] (Appendix A). * For standard phase 1a and expanded cohort (1b): Patients must all have at least one measurable disease site using criteria provided in section 11. * Relapsed or refractory (R/R) disease, after at least 1 prior treatment regimen as per disease staging (including but not limited to oral bexarotene, interferon, any oral or IV HDAC inhibitor, any topical, oral or IV chemotherapy drugs, radiotherapy, retinoids, topical steroids, systemic steroids, phototherapy, immunomodulators, Biologics and others based on PI discretion. Refer to section 2.1 of the protocol for more details). * Refractory disease is defined as lack of objective response (i.e., partial or complete response) to most recent therapy. * Relapsed disease is defined as recurrent disease after prior therapy that does not qualify as refractory disease. * Other systemic treatments not specified may be allowed based on PI judgement in consultation with the Sponsor. * For primary cutaneous lymphomas, stage IB, II, III and IV according to the TNMB system (Appendix C) are eligible. For primary nodal lymphomas, patients with stages II-IV according to the Ann Arbor staging system are eligible. * Minimum of 4 weeks must have elapsed since last systemic treatment or radiation therapy treatment (or 6 weeks for any nitrosourea-containing regimens), and patients must have recovered from all toxicity of last treatment. If the PI assesses that it is in the best interest of the patient to have a shorter washout period, they may submit a written request to the sponsor and can enroll the patient after written approval has been received. * Age ≥18 years. Both genders are included. However, women of childbearing potential must have a negative B-HCG serum pregnancy test (see Section 10 Study Calendar, Pre-Study, footnote b) and agree to use effective contraceptive methods for the duration of the study. A urine pregnancy test is required just prior to the first dosing session of every treatment cycle. * ECOG performance status 0-1 (Karnofsky ≥60%, see Appendix B). * Life expectancy greater than 6 months. * Patients must have normal organ and marrow function as defined below: * Leukocytes ≥ 3,000/μL * Absolute neutrophil count ≥ 1,500/μL * Platelets ≥ 100,000/μL * Total bilirubin within normal institutional limits. Patients with total bilirubin ≤ 1.5 X upper limit of normal are eligible * AST (SGOT) and ALT (SGPT) within institutional upper limit of normal * Creatinine clearance ≥60 mL/min/1.73m2 by the Modification of Diet in Renal Disease (MDRD) equation * Absolute neutrophil count ≥ 500/μL * Platelets ≥ 50,000/μL * Triglyceride blood level (fasting) \<300mg/dL at time of enrollment (normal: \<150mg/dL; borderline high = 150-199mg/dL; high = 200-499mg/dL; very high = 500mg/dL or higher). * ST-001 is an experimental drug and the risks to the unborn or nursing child are unknown. Pregnant or breastfeeding women cannot take part in this study. Women of childbearing age are required to have a blood and/or urine pregnancy test before beginning the investigational study treatment. If you are sexually active, it is important that you not become pregnant or father a child because this medication may be harmful to your unborn child. Patients must discuss pregnancy plans with their doctor before enrolling in this study and agree that they will take the appropriate precautions not to become pregnant while enrolled in the study.	* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients who are receiving any other investigational agents. * Patients with known or history of central nervous system (CNS) disease are excluded from this clinical trial because of their poor prognosis and because of concerns regarding toxicity attribution. * History of allergic reactions or sensitivity to retinoids or to any excipients of ST-001. * Concomitant drug administration. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY heart classification III/IV), unstable angina pectoris, cardiac arrhythmia, QTc interval \>450 milliseconds on baseline triplicate ECG, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because ST-001is a retinoid agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ST-001, breastfeeding should be discontinued if the mother is treated with ST-001. * HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ST-001. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. * Patients with any active hepatitis infections. * Presence of nyctalopia (night blindness), or hemeralopia (defective vision in a bright light, 'day blindness') at enrollment, or any other retinal, ophthalmological condition (eg: retinitis pigmentosa, choroidoretinitis and xerophthalmia), and glaucoma. * Patients who have received prior fenretinide systemic therapy * Patients with T-cell lymphoma types other than those specified in section 3.1.1 are not eligible even if they have cutaneous dissemination. Similarly, patients with any type of natural killer (NK)- or B-cell lymphoma are not eligible regardless of sites of involvement by disease.

Inclusion Criteria

Exclusion Criteria

* All patients must have histologically or cytologically confirmed diagnosis of the following specific types of T-cell lymphomas (TCL):
1. Cutaneous T-cell lymphoma (CTCL): mycosis fungoides (MF), Sézary Syndrome (SS), or primary cutaneous CD30+ anaplastic large cell lymphoma (cALCL).
2. Nodal TCL: Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), or follicular T-cell lymphoma (FTCL) as defined in the 2016 revision of the WHO classification of lymphoid malignancies\[98\] (Appendix A).
* For standard phase 1a and expanded cohort (1b): Patients must all have at least one measurable disease site using criteria provided in section 11.
* Relapsed or refractory (R/R) disease, after at least 1 prior treatment regimen as per disease staging (including but not limited to oral bexarotene, interferon, any oral or IV HDAC inhibitor, any topical, oral or IV chemotherapy drugs, radiotherapy, retinoids, topical steroids, systemic steroids, phototherapy, immunomodulators, Biologics and others based on PI discretion. Refer to section 2.1 of the protocol for more details).
* Refractory disease is defined as lack of objective response (i.e., partial or complete response) to most recent therapy.
* Relapsed disease is defined as recurrent disease after prior therapy that does not qualify as refractory disease.
* Other systemic treatments not specified may be allowed based on PI judgement in consultation with the Sponsor.
* For primary cutaneous lymphomas, stage IB, II, III and IV according to the TNMB system (Appendix C) are eligible. For primary nodal lymphomas, patients with stages II-IV according to the Ann Arbor staging system are eligible.
* Minimum of 4 weeks must have elapsed since last systemic treatment or radiation therapy treatment (or 6 weeks for any nitrosourea-containing regimens), and patients must have recovered from all toxicity of last treatment. If the PI assesses that it is in the best interest of the patient to have a shorter washout period, they may submit a written request to the sponsor and can enroll the patient after written approval has been received.
* Age ≥18 years. Both genders are included. However, women of childbearing potential must have a negative B-HCG serum pregnancy test (see Section 10 Study Calendar, Pre-Study, footnote b) and agree to use effective contraceptive methods for the duration of the study. A urine pregnancy test is required just prior to the first dosing session of every treatment cycle.
* ECOG performance status 0-1 (Karnofsky ≥60%, see Appendix B).
* Life expectancy greater than 6 months.
* Patients must have normal organ and marrow function as defined below:
* Leukocytes ≥ 3,000/μL
* Absolute neutrophil count ≥ 1,500/μL
* Platelets ≥ 100,000/μL
* Total bilirubin within normal institutional limits. Patients with total bilirubin ≤ 1.5 X upper limit of normal are eligible
* AST (SGOT) and ALT (SGPT) within institutional upper limit of normal
* Creatinine clearance ≥60 mL/min/1.73m2 by the Modification of Diet in Renal Disease (MDRD) equation
* Absolute neutrophil count ≥ 500/μL
* Platelets ≥ 50,000/μL
* Triglyceride blood level (fasting) \<300mg/dL at time of enrollment (normal: \<150mg/dL; borderline high = 150-199mg/dL; high = 200-499mg/dL; very high = 500mg/dL or higher).
* ST-001 is an experimental drug and the risks to the unborn or nursing child are unknown. Pregnant or breastfeeding women cannot take part in this study. Women of childbearing age are required to have a blood and/or urine pregnancy test before beginning the investigational study treatment. If you are sexually active, it is important that you not become pregnant or father a child because this medication may be harmful to your unborn child. Patients must discuss pregnancy plans with their doctor before enrolling in this study and agree that they will take the appropriate precautions not to become pregnant while enrolled in the study.

* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
* Patients who are receiving any other investigational agents.
* Patients with known or history of central nervous system (CNS) disease are excluded from this clinical trial because of their poor prognosis and because of concerns regarding toxicity attribution.
* History of allergic reactions or sensitivity to retinoids or to any excipients of ST-001.
* Concomitant drug administration.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY heart classification III/IV), unstable angina pectoris, cardiac arrhythmia, QTc interval \>450 milliseconds on baseline triplicate ECG, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women are excluded from this study because ST-001is a retinoid agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ST-001, breastfeeding should be discontinued if the mother is treated with ST-001.
* HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ST-001. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
* Patients with any active hepatitis infections.
* Presence of nyctalopia (night blindness), or hemeralopia (defective vision in a bright light, 'day blindness') at enrollment, or any other retinal, ophthalmological condition (eg: retinitis pigmentosa, choroidoretinitis and xerophthalmia), and glaucoma.
* Patients who have received prior fenretinide systemic therapy
* Patients with T-cell lymphoma types other than those specified in section 3.1.1 are not eligible even if they have cutaneous dissemination. Similarly, patients with any type of natural killer (NK)- or B-cell lymphoma are not eligible regardless of sites of involvement by disease.

Contacts and Locations

Study Contact

Louis M Scarmoutzos, PhD

CONTACT

(617) 283-2182

lou@scitechdevelopment.com

Principal Investigator

Ali Moiin, MD

STUDY_DIRECTOR

SciTech Development, LLC

Oleg E Akilov, MD, PhD

PRINCIPAL_INVESTIGATOR

University of Pittsburgh Medical Center (UPMC)

Ann F Mohrbacher, MD

PRINCIPAL_INVESTIGATOR

University of Southern California

Barbara Pro, MD

PRINCIPAL_INVESTIGATOR

Columbia University

Dipenkumar Modi, MD

PRINCIPAL_INVESTIGATOR

Barbara Ann Karmanos Cancer Institute

Auris O Huen, MD, PharmD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Ryan A Wilcox, MD, PhD

PRINCIPAL_INVESTIGATOR

University of Michigan

Brad Haverkos, M.D.

PRINCIPAL_INVESTIGATOR

University of Colorado - Anschutz Medical Campus

Study Locations (Sites)

University of Southern California

Los Angeles, California, 90007

United States

University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045

United States

University of Michigan

Ann Arbor, Michigan, 48109

United States

Barbara Ann Karmanos Cancer Institute Wayne State University

Detroit, Michigan, 48201

United States

Columbia University

New York, New York, 10032

United States

University of Pittsburgh Medical Center (UPMC)

Pittsburgh, Pennsylvania, 15219

United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: SciTech Development, LLC

Ali Moiin, MD, STUDY_DIRECTOR, SciTech Development, LLC
Oleg E Akilov, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh Medical Center (UPMC)
Ann F Mohrbacher, MD, PRINCIPAL_INVESTIGATOR, University of Southern California
Barbara Pro, MD, PRINCIPAL_INVESTIGATOR, Columbia University
Dipenkumar Modi, MD, PRINCIPAL_INVESTIGATOR, Barbara Ann Karmanos Cancer Institute
Auris O Huen, MD, PharmD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
Ryan A Wilcox, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Michigan
Brad Haverkos, M.D., PRINCIPAL_INVESTIGATOR, University of Colorado - Anschutz Medical Campus

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-18

Study Completion Date2025-11

Study Record Updates

Study Start Date2023-12-18

Study Completion Date2025-11

Terms related to this study

Keywords Provided by Researchers

Lymphoma
CTCL
Sézary syndrome
mycosis fungoides
PTCL
AITL
cALCL

Additional Relevant MeSH Terms

T-cell Lymphoma
Cutaneous/Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Classified
Primary Cutaneous T-cell Lymphoma
Cutaneous T-Cell Lymphoma, Unspecified
Cutaneous T-cell Lymphoma
Follicular T-Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Sézary's Disease
Mycosis Fungoides